February 24, 2017
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Notice concerning the Appointment of the Representative Directorand Nominations for the Board of Directors/ Auditor Candidates

SymBio Pharmaceuticals Limited (“the Company”) announces that at a Board of Directors’ Meeting held
today, it has been decided to formally propose the approval of the appointment of a new Representative
Director of the Company at the 12th Ordinary General Meeting of Shareholders to be held on March 29,
2017, (the “Shareholders Meeting”) and at the Board of Directors’ Meeting (the “Directors Meeting”) to beheld immediately following the Shareholders Meeting.
The Company shall also submit a proposal to the Shareholders Meeting on the election of the Company’s
Directors and Auditors as follows.
1.

Nomination of Candidates for Representative Director (Newly nominated)(1) Reason for Nomination
In order to further strengthen the Company’s management organization, aiming to increase its
corporate value.
(2) Name and New Title
Mr. Kazuo Asakawa, Representative Director, Executive Vice President, COO and Head of theCompany’s Japan Business Unit
(3) Date of Assumption of Office
March 29, 2017(4) Profile of the Candidate
Number ofDate of Birth

Career Summary

CompanyShares OwnedApril 1979

February 25,
1954

December 1994
June 1996
April 1997

Joined Sandoz Japan K.K.
General Manager, Central Nervous System Unit,
Nippon Roche K.K.
Group Manager, Special Products Group,
Sandoz Japan K.K.
General Manager, Marketing Department,
Novartis Pharma K.K.

1None

Corporate Officer, Head of Transplantation &April 2002

Immunology Business Division,
Novartis Pharma K.K.
Executive Director, Head of Oncology Business

December 2005

Unit, Novartis Pharma K.K.
Joined the Company

December 2015

Head of the Company’s Japan Business Unit
Corporate Officer, Executive Vice President,

March 2016

COO, and Head of the Company’s Japan
Business Unit (current positions)(Significant concurrent position)
Not applicable＊

Mr. Kazuo Asakawa is expected to be appointed as a member of the Company’s Board of Directors
at the Shareholders Meeting.

2.

Nomination of Candidates as Members of the Board of Directors and as Auditors (As of March 29, 2017)(1) Nomination of Candidates as Members of the Board of Directors (Re-nomination)
Mr. Fuminori Yoshida, Representative Director, President & CEOMs. Naoko Iino, Outside Director
Dr. George Morstyn, Outside Director
Dr. Milton Grannatt, Outside Director(2) Nomination of Candidates as Members of the Board of Directors (Newly nominated)
Mr. Kazuo Asakawa＊

Mr. Kazuo Asakawa is expected to be newly appointed as the Company’s Representative Directorand Executive Vice President at the Directors Meeting after being newly appointed as a member ofthe Company’s Board of Directors at the Shareholders Meeting. For Mr. Asakawa’s profile, pleaserefer to “1. Nomination of Candidates for Representative Director (Newly nominated)”(3) Nomination of Candidates as Members of the Board of Directors (Outside Directors) (Newlynominated)
Mr. Sumio Ariyoshi
Profile of the Candidate
Date of Birth

CareerSummary

October 11, 1951
April 1974

Joined Mitsubishi Corporation

June 1992

President & CEO, MC Medical, Inc.

April 2006

Senior Vice President, Division COO, Human Care BusinessDiv., Mitsubishi Corporation

April 2011

Representative Director and President, MC Healthcare, Inc.

October 2016

Advisor, SHINRYO CO., LTD. (current)2(4) Nomination of Candidates for Outside Auditors (Newly nominated)
Mr. Kiyoshi Watanabe (Full-time)
Profile of the Candidate
Date of Birth May 16, 1951
April 1974

Joined The Industrial Bank of Japan, Limited(currently Mizuho Bank, Ltd.)
Chief of The Americas Corporate Credit Office, Credit

June 1998

Department, The Industrial Bank of Japan, Limited(resided in New York)

June 2003
CareerSummary

April 2005

October 2008

February 2011

June 2015

General Manager, Corporate Planning Office,Kyowa Hakko Kogyo Co., Ltd.
General Manager, Medicine Planning Department,
Kyowa Hakko Kogyo Co., Ltd.
General Manager, Planning and Administration Department,
KYOWA HAKKO BIO CO., LTD.
Full-time Audit & Supervisory Board Member,
Kawaguchi Chemical Industry Co., Ltd.
Member of the Audit & Supervisory Board,
Toho Acetylene Co., Ltd. (current)

Mr. Shigetoshi Matsumoto
Profile of the Candidate
Date of BirthAugust 12, 1949
April 1972
April 2002

March 2007
CareerSummary

Joined CHUGAI PHARMACEUTICAL CO., LTD.
General Manager of the Audit Office,
CHUGAI PHARMACEUTICAL CO., LTD.
Full-time Audit & Supervisory Board Member,
CHUGAI PHARMACEUTICAL CO., LTD.

April 2011

Senior Advisor, CHUGAI PHARMACEUTICAL CO., LTD.

October 2011

Advisor, APO PLUS STATION Co., Ltd.

June 2015

Senior Advisor, Protiviti LLC

October 2015

Audit Practice Counselor,
Japan Audit & Supervisory Board Members Association (current)33.

Members of the Board of Directors and the Auditors who shall resign(1) Board of Directors
Mr. Lowell Sears, Outside Director
Mr. George Vandeman, Outside Director(2) Auditors
Mr. Takeshi Masuda, Outside Auditor (Full-time)
Mr. Chikara Shimazaki, Outside Auditor[Contact]
Investor Relations
Tel: +81 (0)3 5472 1125

4